Axolotl provides HIE suite for reporting and analytics

Jeff Byers | | Health Exec | Informatics
Health information exchange (HIE) services company Axolotl has introduced Elysium Discover, a suite of reporting and analytic tools designed specifically for HIEs.

Elysium Discover provides a platform that is integrated with an HIE to deliver reporting, analytics and dashboard capabilities, according to the San Jose, Calif.-based Axolotl.

The suite includes a range of data marts, pre-built reports and purpose-built dashboards to satisfy the reporting and analytics needs in areas such as HIE administration, clinical quality and public health while providing an open platform for custom reporting and analytics development as well as enforcing security controls, the company added.

Jeff Byers

Related Content

Alabama security breach exposes personal information of cardiologists, heart patients
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Best in KLAS 2024: New rankings for cardiovascular information systems, hemodynamic solutions
Best in KLAS 2024 rankings released, showcasing medical imaging IT systems
Cloud image storage for radiology is a growing trend in healthcare
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.